Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Research and development (“R&D”) expenses, net $ 4,929 $ 5,670
Amortization of intangible assets 380 379
General and administrative expenses 2,477 2,493
Operating loss 7,786 8,542
Interest expenses 461
Finance income, net (87) (143)
Loss before tax 8,160 8,399
Tax expenses 9 3
Net loss $ 8,169 $ 8,402
Basic and diluted loss per share of Common Stock (in Dollars per share) $ 0.27 $ 0.35
Weighted average number of shares of Common Stock outstanding, basic and diluted (in Shares) 29,754,240 23,944,573